OncologyTube

04/21/2025

🚨 Sotorasib + Panitumumab cuts death risk by 30% (HR 0.70) in KRAS G12C colorectal cancer

CodeBreaK 300’s 30.2% response rate- Will it redefine treatment?

ARTICLE: https://oncologytube.com/sotorasib-lumakras-panitumumab-vectibix-codebreak-300-shows-promise-in-kras-g12c-mutated-colorectal-cancer/

04/17/2025

🚨 ASCO 2025 SLNB Guidelines: Skipping lymph node biopsies for low-risk breast cancer could save lives AND lower costs...

But are we doing enough for Black patients? 12% vs 8% lymphedema rates raise tough questions. What’s your take?

ARTICLE: https://oncologytube.com/asco-2025-guidelines-on-sentinel-lymph-node-biopsy-for-early-stage-breast-cancer-a-game-changer-in-oncology/

YouTube: https://youtu.be/b99XsnVa7Bo

X: https://x.com/oncologytube/status/1912992296670494836

LinkedIn: https://www.linkedin.com/posts/oncologytube%2Ecom_asco-2025-guidelines-on-sentinel-lymph-node-activity-7318759134101680128-oaKQ?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAA7noEBEghxpLh9c9mWhEgsINbVKGhRiqg

04/10/2025

It’s Conference Season! 🎉 Oncologists 🥼and Cancer Professionals👩‍⚕️, plan for 2025 and beyond with the ultimate Oncology Conferences list📅! ASCO, SABCS, ESMO & more—dates, locations, and details await. Don’t miss the action! 🔗

https://oncologytube.com/oncology-conferences-2025-2027-full-list-details/

04/02/2025

🫁 Lung Cancer Updates 2025! Dr. Hamid Mirshahidi, MD (Loma Linda University) shares:

1️⃣ "T1 N2A used to be stage 3A, now is a stage 2B."
2️⃣ "A combination of chemoemotherapy preoperatly can help us to make this non-respectable stage treeung cancer as this respectable lung cancer."
3️⃣ "2024 was minstone for stage three and four lung cancer with new approval."

ARTICLE: https://oncologytube.com/lung-cancer-2025-updates-in-staging-and-treatment-aacr-9th-edition-and-beyond/
YouTube: https://youtu.be/ZvK82pIN3so
X.com: https://x.com/oncologytube/status/1907469813380989330

This link will take you to a page that’s not on LinkedIn

04/01/2025

Big updates from MOASC 2025! Dr. Evanthia Roussos Torres, MD, shares the latest on breast cancer treatment: 'It’s a lot to ask of patients to take on the risk of a lifelong autoimmune disease because of a therapy that cured their breast cancer.' She’s calling for better biomarkers and smarter use of immunotherapy to balance risks and rewards. Check out her full talk to see how research is shaping the future of care!

ARTICLE: https://oncologytube.com/2025-breast-cancer-updates-dr-evanthia-roussos-torres-on-biomarkers-immunotherapy-and-the-future-of-treatment-moasc/
https://youtu.be/KSNaIM4yjkw

Article: https://oncologytube.com/2025-breast-cancer-updates-dr-evanthia-roussos-torres-on-biomarkers-immunotherapy-and-the-future-of-treatment-moasc/Join Ev...

03/31/2025

"We do think we're curing roughly 30 to 40% of those patients." refering to DLBCL (diffuse large B-cell lymphoma)

2025 Leukemia / Lymphoma Updates

Dr. Aaron Goodman, MD -
UC San Diego Health UC San Diego School of Medicine

Article: https://oncologytube.com/2025-leukemia-lymphoma-updates-with-aaron-goodman-md-uc-san-diego-moasc/
YouTube: https://youtu.be/Sp5-a3cwxYM

Explore the latest advancements discussed at the 2025 Leukemia Lymphoma Updates for patients facing blood disorders.

03/27/2025

Big congrats to Dr. Peter Zang, a second-year fellow at @ , for winning the 2025 Cary Presant, MD Investigator Award from MOASC (Medical Oncology Association of Southern California)! 🎉 This amazing honor comes with a $25,000 research grant from AVEO Oncology to support his work. Dr. Zang is researching a new treatment (ABBV-969) for metastatic castrate-resistant prostate cancer, inspired by his patients who ask, “How are these treatments affecting my cancer?” He says, “We have great treatments, but most aren’t curative—so we need to understand them better.” With this award, he’ll dive deeper into how cancer responds to therapy to help patients even more. A big shoutout to his incredible mentors at City of Hope—Dr. Tanya Dorf, Dr. Monty Pav, and Dr. Ravi Salia—for their support. We’re so excited to see where this research takes us! .zang5

Read Article and Watch Video Interview Here: https://oncologytube.com/moasc-awards-25000-research-grant-from-aveo-oncology-to-dr-peter-zang-md-of-city-of-hope-2025-cary-presant-md-investigator-award/

https://youtu.be/VAjuwC1C5gY

Go to https://moasc.org/ for more information on this important organization.Dr. Peter Zang, MD a second-year fellow at City of Hope, shares his excitement a...

02/28/2025

🚨 BREAKING: Dr. Jose R. Conejo-Garcia unveils a game-changing immunotherapy discovery at ! Antibodies in TLS could stop cancer progression. American Association for Cancer Research (AACR) Cancer Institute Society for Immunotherapy of Cancer

Dive into the article: https://oncologytube.com/immunotherapy-revolution-unveiled-how-tls-derived-antibodies-are-changing-cancer-treatment-aacr-io-2025/
YouTube: https://youtu.be/yK89KZ_pfoU
Join 17,000 Medical Professionals on our eNewsletter: https://oncologytube.com/newsletter/

02/21/2025

Can MRI Safely Skip Prostate Biopsies? 3-Year Study Results

Article: https://oncologytube.com/mris-role-in-prostate-cancer-diagnosis-a-3-year-study-breakthrough/
YouTube: https://youtu.be/agcxD8bVYyk

Cancer Society Prostate Cancer Foundation

02/20/2025

FDA Approves Enhertu for HR+/HER2-low Breast Cancer: Key Trial Results & Insights
ology U.S. Food and Drug Administration

Article: https://oncologytube.com/fda-approves-enhertu-for-hr-her2-low-breast-cancer-key-trial-results-insights/
YouTube: https://youtu.be/F-nNg3FrGGw

American Society of Clinical Oncology MD Anderson Cancer Center

The FDA approves Enhertu, bringing new hope for patients with advanced HR-positive, HER2-low breast cancer.

02/19/2025

FDA Approves Deciphera Vimseltinib / Romvimza for symptomatic tenosynovial giant cell tumor (TGCT) @

Article: https://oncologytube.com/fda-approves-deciphera-vimseltinib-romvimza-for-symptomatic-tenosynovial-giant-cell-tumor-tgct-patients/
YouTube: https://youtu.be/B_pW8JZsa4Q

02/18/2025

iVIDEO: Is Enfortumab Vedotin + Pembrolizumab the Paradigm Shift Chemo Can't Compete With for la/mUC? - EV-302 Phase 3 Update at American Society of Clinical Oncology Barts Cancer Institute (Queen Mary University of London)

Article: https://oncologytube.com/enfortumab-vedotin-plus-pembrolizumab-vs-chemotherapy-for-untreated-la-muc-ev-302-study-update/
YouTube: https://youtu.be/gUmqFouzvdY